448 THERAPEUTICS
448 Therapeutics focuses on the research and experimental development of biotechnology. It is a biotechnology company that engages in creating novel immuno-oncology drugs.
448 THERAPEUTICS
Industry:
Biotechnology Life Science Product Research
Address:
Nottingham, Nottingham, United Kingdom
Country:
United Kingdom
Status:
Active
Similar Organizations
FibromEd
FibromEd is provides a research and experimental development on biotechnology.
GeneWake GmbH
GeneWake GmbH focuses on contract research in the vast field of biomarker analysis for oncology.
Islexa
Islexa is provides research and experimental development on biotechnology.
TFL Bearing
TFL focuses on the research and development of bearing technology.
Current Employees Featured
Founder
More informations about "448 THERAPEUTICS"
448 THERAPEUTICS LTD - LinkedIn
Advanced technology & innovation centre loughborough university science park 5 oakwood drive loughborough, le11 3qf, gbSee details»
448 Therapeutics - Products, Competitors, Financials, Employees ...
448 Therapeutics works in research and experimental development on biotechnology. Use the CB Insights Platform to explore 448 Therapeutics's full profile. 448 Therapeutics - Products, …See details»
Mark Graham - Founder @ 448 THERAPEUTICS - Crunchbase
Mark Graham is the Founder at 448 THERAPEUTICS. Jobs. Edit Jobs Section. Number of Current Jobs 2. Number of Past Jobs 1. Mark Graham has 2 current jobs as Founder at 448 …See details»
448 THERAPEUTICS LTD - Companies House
More for 448 THERAPEUTICS LTD (10311878) Registered office address Biocity Nottingham, Pennyfoot Street, Nottingham, Nottinghamshire, England, NG1 1GF . Company status …See details»
448 THERAPEUTICS - Contacts, Employees, Board Members
448 THERAPEUTICS focuses on the research and experimental development of biotechnology.See details»
448 Therapeutics Ltd Company Number 10311878 Prepared By …
Apr 22, 2024 Name 448 THERAPEUTICS LTD. Company Number 10311878. Company Type Private Limited Company. Company Status Active. SIC Code 72110 Research and …See details»
448 THERAPEUTICS LTD filing history - Find and update company ...
448 THERAPEUTICS LTD - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business …See details»
> 448 Therapeutics - VentureRadar
BiVictriX Therapeutics United Kingdom n/a Established in 2016, BiVictriX Therapeutics Ltd is a North-West based biotech focused on developing and licensing novel, highly-selective, …See details»
448 Therapeutics Ltd - Nottingham NG1 1GF (Nottinghamshire
Dec 2, 2022 448 THERAPEUTICS LTD offers research and experimental development on biotechnology. Incorporated in 2016 with the registration number 10311878, 448 …See details»
448 Therapeutics - CB Insights
Explore {448 Therapeutics's key management people. Discover current leadership team members including founders, CEO, other executives and board directors. 448 Therapeutics CEO, …See details»
448 Therapeutics Ltd. (448 Therapeutics Ltd.) - 药物管线_专利_临 …
了解448 Therapeutics Ltd. (448 Therapeutics Ltd.)公司的药物管线，治疗领域，技术平台，以及它的。See details»
448 Therapeutics Ltd - Company Profile - Endole
448 Therapeutics Ltd is an active company located in . View company profile, shareholders, contacts, financials, industry and description. Meet Endole Features Solutions Pricing …See details»
Patient-reported outcomes from the MIRASOL trial evaluating ...
Apr 1, 2025 MIRV did not seem to impair or improve patient quality of life compared with investigator's choice of chemotherapy. The similar quality-of-life outcomes in the two treatment …See details»
GSK joins anti-TIGIT push with $625m upfront iTeos deal
5 days ago The deal includes $625 million in upfront fees to secure rights to EOS-448, which is currently in a phase 1 dose-ranging trial in advanced solid tumours in combination with GSK's …See details»
20250425xFOREST Therapeutics Announces Drug Discovery …
6 days ago This technology has the potential to deliver novel therapeutics for diseases that have been difficult to treat with conventional drug discovery approaches. Through this collaboration, …See details»
20250425 | xFOREST Therapeutics、複数疾患でのRNAスプライシ …
6 days ago 株式会社イクスフォレストセラピューティクス（本社：京都府京都市上京区、代表取締役社長ceo：樫田俊一、代表取締役cto：小松リチャード馨、以下、xforest社）は、アス …See details»
GSK and iTeos Therapeutics announce development and …
Obligation to share responsibility and costs for the global development of EOS-448; our plan to accelerate and expand the clinical development of EOS-448 and other in-house pipeline …See details»
Cancer chemoprevention: signaling pathways and strategic …
Apr 18, 2025 Although cancer chemopreventive agents have been confirmed to effectively protect high-risk populations from cancer invasion or recurrence, only over ten drugs have …See details»
448 THERAPEUTICS - Tech Stack, Apps, Patents & Trademarks
Experience the new Crunchbase, powered by AI . Organization. 448 THERAPEUTICSSee details»
GSK, iTeos take stock after Roche's TIGIT setback
3 days ago iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for …See details»